Gotham Asset Management LLC Cuts Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Gotham Asset Management LLC trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 46.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,074 shares of the specialty pharmaceutical company's stock after selling 24,032 shares during the quarter. Gotham Asset Management LLC owned 0.09% of Collegium Pharmaceutical worth $804,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COLL. Barclays PLC grew its stake in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after buying an additional 45,291 shares during the last quarter. Franklin Resources Inc. lifted its position in Collegium Pharmaceutical by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock worth $1,164,000 after acquiring an additional 3,620 shares during the period. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the period. Exchange Traded Concepts LLC lifted its position in Collegium Pharmaceutical by 4.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 75,095 shares of the specialty pharmaceutical company's stock worth $2,151,000 after acquiring an additional 3,402 shares during the period. Finally, KBC Group NV lifted its position in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after acquiring an additional 982 shares during the period.

Wall Street Analyst Weigh In

COLL has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Insider Activity

In related news, CFO Colleen Tupper sold 1,949 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares of the company's stock, valued at approximately $5,315,850. This represents a 1.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. The trade was a 1.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock valued at $2,334,994 in the last quarter. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded up $0.04 on Friday, hitting $28.86. The company had a trading volume of 178,265 shares, compared to its average volume of 427,975. The firm has a market cap of $927.33 million, a P/E ratio of 12.44 and a beta of 0.63. The company has a 50-day moving average price of $28.11 and a 200-day moving average price of $29.71. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period last year, the firm earned $1.45 EPS. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.